Close Menu

Editas Medicine says that it will be testing CRISPR-based gene editing in people by 2017, according to Technology Review.

At the EmTech conference, CEO Katrine Bosley said the startup — co-founded by the Broad Institute's Feng Zhang — plans to start a clinical trial within two years to test the use of gene editing to treat Leber congenital amaurosis, a rare form of blindness affecting the retina.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.